{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:19:29Z","timestamp":1740122369290,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10552-016-0779-5","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T22:09:45Z","timestamp":1467238185000},"page":"1009-1017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer\u00a0screening trial"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5398-761X","authenticated-orcid":false,"given":"Roni T.","family":"Falk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annetine Cathrine","family":"Staff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Bradwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Ananth","family":"Karumanchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Troisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,29]]},"reference":[{"issue":"supplement 1","key":"779_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.5-suppl_1-37","volume":"5","author":"G Gasparini","year":"2000","unstructured":"Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(supplement 1):37\u201344","journal-title":"Oncologist"},{"key":"779_CR2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0046-8177(95)90119-1","volume":"26","author":"LF Brown","year":"1995","unstructured":"Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF et al (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86\u201391","journal-title":"Hum Pathol"},{"key":"779_CR3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1677\/erc.1.00931","volume":"13","author":"SM Hyder","year":"2006","unstructured":"Hyder SM (2006) Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr Relat Cancer 13:667\u2013687","journal-title":"Endocr Relat Cancer"},{"key":"779_CR4","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.humpath.2008.06.004","volume":"39","author":"S Ghosh","year":"2008","unstructured":"Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL et al (2008) High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39:1835\u20131843","journal-title":"Hum Pathol"},{"issue":"1","key":"779_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10549-012-1957-0","volume":"133","author":"E Maae","year":"2012","unstructured":"Maae E, Olsen DA, Steffensen KD, Jakobsen EH, Brandslund I, S\u00f8rensen FB et al (2012) Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat 133(1):257\u2013265. doi: 10.1007\/s10549-012-1957-0","journal-title":"Breast Cancer Res Treat"},{"key":"779_CR6","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.ejca.2005.07.022","volume":"4","author":"C Parr","year":"2005","unstructured":"Parr C, Watkins G, Boulton M, Cai J, Jiang WG (2005) Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 4:2819\u20132827","journal-title":"Eur J Cancer"},{"key":"779_CR7","first-page":"293","volume":"20","author":"A Thielemann","year":"2013","unstructured":"Thielemann A, Baszczuk A, Kopczy\u0144ski Z, Kopczy\u0144ski P, Grodecka-Gazdecka S (2013) Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer. Ann Agric Environ Med 20:293\u2013297","journal-title":"Ann Agric Environ Med"},{"key":"779_CR8","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/sj.bjc.6600956","volume":"88","author":"T Bachelot","year":"2003","unstructured":"Bachelot T, Ray-Coquard I, Menetrier_Caux C, Rastkha M, Duc A, Blay JY (2003) Prognostic value of serum levels of interleukin 6 and or serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721\u20131726","journal-title":"Br J Cancer"},{"key":"779_CR9","first-page":"3481","volume":"27","author":"GJ Byrne","year":"2007","unstructured":"Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ (2007) Serum vascular endothelial growth factor in breast cancer. Anticancer Res 27:3481\u20133487","journal-title":"Anticancer Res"},{"key":"779_CR10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10552-008-9252-4","volume":"20","author":"KW Reeves","year":"2009","unstructured":"Reeves KW, Ness RB, Stone RA, Weissfeld JL, Vogel VG, Powers RW et al (2009) Vascular endothelial growth factor and breast cancer risk. Cancer Causes Control 20:375\u2013386","journal-title":"Cancer Causes Control"},{"key":"779_CR11","first-page":"3491","volume":"7","author":"K Heer","year":"2001","unstructured":"Heer K, Kumar H, Read JR, Fox JN, Monson JRT, Kerin MJ (2001) Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 7:3491\u20133494","journal-title":"Clin Cancer Res"},{"key":"779_CR12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5301\/JBM.2008.5323","volume":"19","author":"FJ Hoar","year":"2004","unstructured":"Hoar FJ, Lip GYH, Belgore F, Stonelake PS (2004) Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFlt-1) in human breast cancer. Int J Biol Markers 19:229\u2013235","journal-title":"Int J Biol Markers"},{"issue":"1","key":"779_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/bjc.2012.195","volume":"107","author":"S Opdahl","year":"2012","unstructured":"Opdahl S, Romundstad PR, Alsaker MDK, Vatten LJ (2012) Hypertensive diseases in pregnancy and breast cancer risk. Br J Cancer 107(1):176\u2013182. doi: 10.1038\/bjc.2012.195","journal-title":"Br J Cancer"},{"key":"779_CR14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bjc.6600581","volume":"87","author":"LJ Vatten","year":"2002","unstructured":"Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R (2002) Pre-eclampsia in pregnancy and subsequent risk for breast cancer. B J Cancer 87:971\u2013973","journal-title":"B J Cancer"},{"key":"779_CR15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00001648-199811000-00014","volume":"9","author":"R Troisi","year":"1998","unstructured":"Troisi R, Weiss HA, Hoover RN (1998) Pregnancy characteristics and maternal risk of breast cancer. Epidemiology 9:641\u2013647","journal-title":"Epidemiology"},{"issue":"6","key":"779_CR16","doi-asserted-by":"crossref","first-page":"653e.1","DOI":"10.1016\/j.ajog.2008.06.030","volume":"199","author":"R Troisi","year":"2008","unstructured":"Troisi R, Braekke K, Harsem NK, Hyer M, Hoover RN, Staff AC (2008) Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. Am J Obstet Gynecol 199(6):653e.1\u2013653e.10","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"779_CR17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10552-015-0577-5","volume":"26","author":"L Carbillon","year":"2015","unstructured":"Carbillon L, Delahosseraye C (2015) Preeclampsia and subsequent breast cancer risk. Cancer Causes Control 26(6):955\u2013956","journal-title":"Cancer Causes Control"},{"issue":"1\u20132","key":"779_CR18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.mrfmmm.2005.06.013","volume":"592","author":"RB Hayes","year":"2005","unstructured":"Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P et al (2005) Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 592(1\u20132):147\u2013154","journal-title":"Mutat Res"},{"issue":"4","key":"779_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/jnci\/djr531","volume":"104","author":"BJ Fuhrman","year":"2012","unstructured":"Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY et al (2012) Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 104(4):326\u2013339. doi: 10.1093\/jnci\/djr531","journal-title":"J Natl Cancer Inst"},{"key":"779_CR20","first-page":"2784","volume":"28","author":"MEH Hammond","year":"2010","unstructured":"Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 28:2784\u20132795","journal-title":"J Oncol Pract"},{"issue":"2","key":"779_CR21","doi-asserted-by":"publisher","first-page":"161.3","DOI":"10.1016\/j.ajog.2009.09.016","volume":"202","author":"X Verlohren","year":"2010","unstructured":"Verlohren X, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG et al (2010) An automated method for the determination of the sFlt-1\/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202(2):161.3\u2013161.e11. doi: 10.1016\/j.ajog.2009.09.016","journal-title":"Am J Obstet Gynecol"},{"key":"779_CR22","volume-title":"SAS\/STAT user\u2019s guide, version 8","author":"SAS Institute Inc.","year":"1999","unstructured":"SAS Institute Inc. (1999) SAS\/STAT user\u2019s guide, version 8. SAS Institute Inc., Cary"},{"key":"779_CR23","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/1055-9965.EPI-09-0207","volume":"18","author":"LJ Vatten","year":"2009","unstructured":"Vatten LJ, Romundstad PR, Jenum PA, Eskild A (2009) Angiogenic balance in pregnancy and subsequent breast cancer risk and survival: a population study. Cancer Epidemiol Biomarkers Prev 18:2074\u20132078","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"779_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3892\/etm.2014.1685","volume":"8","author":"J Zhang","year":"2014","unstructured":"Zhang J, Yin L, Wu J, Zhang Y, Xu T, Ma R et al (2014) Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinoma. Exp Ther Med 8(1):175\u2013180. doi: 10.3892\/etm.2014.1685","journal-title":"Exp Ther Med"},{"issue":"4","key":"779_CR25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3892\/ol_00000129","volume":"1","author":"J Stathopoulos","year":"2010","unstructured":"Stathopoulos J, Armakolas A, Stathopoulos GP, Gomatos IP (2010) Plasma VEGF levels in breast cancer patients with and without metastases. Oncol Lett 1(4):739\u2013741. doi: 10.3892\/ol_00000129","journal-title":"Oncol Lett"},{"key":"779_CR26","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbal","year":"2008","unstructured":"Kerbal RS (2008) Molecular origins of cancer: tumor angiogenesis. N Engl J Med 358:2039\u20132049","journal-title":"N Engl J Med"},{"key":"779_CR27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00441-006-0159-7","volume":"325","author":"S Garvin","year":"2006","unstructured":"Garvin S, Nilsson UW, Huss FRM, Kratz G, Dabrosin C (2006) Estradiol increases VEGF in human breast studied by whole-tissue culture. Cell Tissue Res 325:245\u2013251","journal-title":"Cell Tissue Res"},{"key":"779_CR28","first-page":"103","volume":"187","author":"C Dabrosin","year":"2005","unstructured":"Dabrosin C (2005) Sex steroid regulation of angiogenesis in breast tissue. Angiogenesis 187:103\u2013108","journal-title":"Angiogenesis"},{"key":"779_CR29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/01.ATV.21.1.6","volume":"21","author":"DW Losordo","year":"2001","unstructured":"Losordo DW, Isner JM (2001) Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 21:115\u2013121","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"779_CR30","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0959-8049(98)00066-5","volume":"34","author":"I Benoy","year":"1998","unstructured":"Benoy I, Vermeulen P, Wuyts H, Dirix L (1998) Vascular endothelial cell growth factor (VEGF) serum concentrations change according to the phase of the menstrual cycle. Eur J Cancer 34:1298\u20131299","journal-title":"Eur J Cancer"},{"key":"779_CR31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0015-0282(99)00476-8","volume":"73","author":"R Agrawal","year":"2000","unstructured":"Agrawal R, Prelevic G, Conway GS, Payne NN, Ginsburg J, Jacobs HS (2000) Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertil Steril 73:56\u201360","journal-title":"Fertil Steril"},{"key":"779_CR32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10815-008-9218-1","volume":"25","author":"P Monteleone","year":"2008","unstructured":"Monteleone P, Artini PG, Simi G, Casarosa E, Cela V, Genazzani AR (2008) Follicular fluid VEGF levels directly correlate with perifollicular blood flow in normoresponder patients undergoing IVF. J Assist Reprod Genet 25:183\u2013186","journal-title":"J Assist Reprod Genet"},{"key":"779_CR33","first-page":"CR45","volume":"12","author":"AP Bailey","year":"2006","unstructured":"Bailey AP, Shparago M, Gu JW (2006) Exercise increases soluble vascular endothelial growth factor receptor-1 (sFlt-1) in circulation of healthy volunteers. Med Sci Monit 12:CR45\u2013CR50","journal-title":"Med Sci Monit"},{"key":"779_CR34","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/sj.ijo.0802987","volume":"29","author":"JV Silha","year":"2005","unstructured":"Silha JV, Krsek M, Sucharda P, Murphy LJ (2005) Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 29:1308\u20131314","journal-title":"Int J Obes"},{"key":"779_CR35","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10552-014-0386-2","volume":"25","author":"LA Prebil","year":"2014","unstructured":"Prebil LA, Ereman RR, Powell MJ, Jamshidian F, Kerlikowske K, Shepherd JA et al (2014) First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes Control 25:859\u2013868. doi: 10.1007\/s10552-014-0386-2","journal-title":"Cancer Causes Control"},{"key":"779_CR36","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/aje\/kwk105","volume":"165","author":"MB Terry","year":"2006","unstructured":"Terry MB, Perrin M, Salafia CM, Zhang FF, Neugut AI, Teitelbaum SL et al (2006) Preeclampsia, pregnancy-related hypertension, and breast cancer risk. Am J Epidemiol 165:1007\u20131012. doi: 10.1093\/aje\/kwk105","journal-title":"Am J Epidemiol"},{"key":"779_CR37","first-page":"3219","volume":"9","author":"HM Verheul","year":"2003","unstructured":"Verheul HM, Pinedo HM (2003) The importance of platelet counts and their contents in cancer. Clin Cancer Res 9:3219\u20133221","journal-title":"Clin Cancer Res"},{"key":"779_CR38","first-page":"149","volume":"17","author":"JK Lee","year":"2000","unstructured":"Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI (2000) Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol 17:149\u2013152","journal-title":"Int J Oncol"},{"key":"779_CR39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/clinchem\/47.4.617","volume":"47","author":"W Jelkmann","year":"2001","unstructured":"Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47:617\u2013623","journal-title":"Clin Chem"},{"key":"779_CR40","first-page":"2898","volume":"60","author":"J Adams","year":"2000","unstructured":"Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V et al (2000) Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60:2898\u20132905","journal-title":"Cancer Res"},{"key":"779_CR41","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/sj.bjc.6600322","volume":"86","author":"C McIlhenny","year":"2002","unstructured":"McIlhenny C, George WD, Doughty JC (2002) A comparison of serum and plasma levels of vascular endothelial growth factor during the menstrual cycle in healthy female volunteers. Br J Cancer 86:1786\u20131789","journal-title":"Br J Cancer"},{"key":"779_CR42","first-page":"3147","volume":"6","author":"ML George","year":"2000","unstructured":"George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI (2000) Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 6:3147\u20133152","journal-title":"Clin Cancer Res"},{"key":"779_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/878209","author":"H Han","year":"2014","unstructured":"Han H, Cao F-L, Wang B-Z, Mu X-R, Li G-Y, Wang X-W (2014) Expression of angiogenesis regulatory proteins and epithelial-mesenchymal transition factors in platelets of the breast cancer patients. Sci World J. doi: 10.1155\/2014\/878209","journal-title":"Sci World J"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-016-0779-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-016-0779-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-016-0779-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T03:58:05Z","timestamp":1600833485000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-016-0779-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,29]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s10552-016-0779-5","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"type":"print","value":"0957-5243"},{"type":"electronic","value":"1573-7225"}],"subject":[],"published":{"date-parts":[[2016,6,29]]}}}